Prognostic impact of body mass index stratified by smoking status in patients with esophageal squamous cell carcinoma

Peng Sun1,2,*
Fei Zhang1,2,*
Cui Chen1,2,*
Chao Ren1,2
Xi-Wen Bi1,2
Hang Yang1,2
Xin An1,2
Feng-Hua Wang1,2
Wen-Qi Jiang1,2

1State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, 2Department of Medical Oncology, Sun Yat-Sen University Cancer Center, 3Department of Oncology, the First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, People’s Republic of China

*These authors contributed equally to this work

Background: As smoking affects the body mass index (BMI) and causes the risk of esophageal squamous cell carcinoma (ESCC), the prognostic impact of BMI in ESCC could be stratified by smoking status. We investigated the true prognostic effect of BMI and its potential modification by smoking status in ESCC.

Methods: We retrospectively analyzed 459 patients who underwent curative treatment at a single institution between January 2007 and December 2010. BMI was calculated using the measured height and weight before surgery. Chi-square test was used to evaluate the relationships between smoking status and other clinicopathological variables. The Cox proportional hazard models were used for univariate and multivariate analyses of variables related to overall survival.

Results: BMI <18.5 kg/m² was a significantly independent predictor of poor survival in the overall population and never smokers after adjusting for covariates, but not in ever smokers. Among never smokers, underweight patients (BMI <18.5 kg/m²) had a 2.218 times greater risk of mortality than non-underweight (BMI ≥18.5 kg/m²) patients (P=0.015). Among ever smokers, BMI <18 kg/m² increased the risk of mortality to 1.656 (P=0.019), compared to those having BMI ≥18 kg/m².

Conclusion: Our study is likely the first to show that the prognostic effect of BMI was substantial in ESCC, even after stratifying by smoking status. Furthermore, the risk of death due to low BMI would be significantly increased in never smokers. We believe that the prognostic impact of BMI is modified but not eliminated by the smoking status in ESCC.

Keywords: esophageal squamous cell carcinoma, ESCC, body mass index, BMI, smoking, prognosis, survival

Introduction

Esophageal cancer is one of the most common digestive cancers worldwide and remains one of the five leading causes of cancer-related deaths in People’s Republic of China.1-3 In Asian Countries such as People’s Republic of China and Japan, esophageal squamous cell carcinoma (ESCC) accounts for >90% of all esophageal cancers with regard to histological classification.4,6 Although a trend toward reduced incidence of ESCC was observed, ESCC remains a serious threat to public health in People’s Republic of China with a poor prognosis.1,2,4 Recent evidence has shown that low body mass index (BMI) increases the risk of developing ESCC, both in the Eastern7 and Western populations.8,9 Meanwhile, the prognostic effect of BMI has been discussed in multiple malignant diseases,10-15 and low BMI is seen as an unfavorable prognostic factor in facilitating appropriate therapeutic strategies for ESCC patients.
Cigarette smoking might affect the prognostic impact of BMI on survival in ESCC. Smoking is known to affect BMI in the general population,\textsuperscript{16–20} in turn attenuating the prognostic effect of BMI in ESCC. However, smoking is an established risk factor\textsuperscript{21} and a potential prognostic factor of ESCC.\textsuperscript{22–25} Therefore, it is necessary to consider smoking status when evaluating BMI and prognosis in ESCC. In 2011, Yoon et al reported their data on esophageal adenocarcinoma and found that the unfavorable prognostic impact of high BMI was limited to never smokers.\textsuperscript{26} However, thus far, to the best of our knowledge, there is no similar data for ESCC. Thus, we hypothesized that the true prognostic value of BMI in ESCC may be better interpreted after stratifying by smoking status, or the effect may be underestimated in the nonsmoking population.

We conducted a retrospective study analyzing a large cohort of patients with ESCC. In order to eliminate the bias of treatment-related malnutrition, we limited the cohort to patients who underwent curative tumor resection and excluded those with preoperative chemotherapy and/or radiotherapy. We aimed to explore the prognostic value of BMI in smokers and nonsmokers who were treated with curative surgery.

**Methods**

**Ethics statement**

All patients provided written consent for their information to be stored in the Sun Yat-Sen University Cancer Center database and used for research. This study was conducted in accordance with the ethical standards of the World Medical Association’s Declaration of Helsinki and approved by an independent ethics committee at the Cancer Center of Sun Yat-Sen University.

**Patients**

We retrospectively reviewed records of patients with ESCC who attended Sun Yat-Sen University Cancer Center between January 2007 and December 2010. All included subjects met the following criteria: 1) presence of pathologically diagnosed ESCC clinically evaluated to be at a localized or locoregional stage (stage I–III according to the sixth edition of the American Joint Committee on Cancer/Union for International Cancer Control Tumor-Node-Metastases [TNM] system); 2) availability of complete clinical data and disease records; and 3) disease management with radical esophagectomy. Patients who underwent preoperative therapy were excluded. Finally, 459 patients were included in the study (Figure 1).

Basic demographics (age, sex) and baseline tumor characteristics (grade, stage) were collected for all patients. Height and weight was measured in the week prior to esophagectomy. Smoking status was recorded for all patients as ever or never smoker. A smoker was defined as an individual who smoked $\geq$1 lifetime pack-years. Alcohol consumers were defined as those who drank any alcoholic beverage one or more times per week. On cessation of treatment, each patient was followed up every 3 months at the clinic or by telephonic contact and interview for at least 5 years. The last follow-up date was December 31, 2015.

**Statistical analyses**

The study’s primary endpoint was overall survival (OS), defined as the time from the date of surgery to the date of death or the last follow-up visit. Patients were categorized by BMI into three subsets: underweight ($<18.5$ kg/m\textsuperscript{2}), normal weight (18.5–24.99 kg/m\textsuperscript{2}), and overweight or obese ($\geq30$ kg/m\textsuperscript{2}).\textsuperscript{27} We used Student’s $t$-test and chi-square tests to compare continuous and categorical variables, respectively, between ever smokers and never smokers.

Given the previous data that underweight (BMI $<18.5$ kg/m\textsuperscript{2}) was associated with poor survival of ESCC,\textsuperscript{28,29} we combined the obese and normal weight groups in the survival analysis. The Kaplan–Meier method was used to estimate the 5-year OS, and the log-rank test was used to determine the survival differences. A stratified log-rank test was conducted with post hoc Bonferroni adjustment. Univariate and multivariate survival analyses were performed based on the Cox proportional hazards regression methodology. Hazard ratios with 95\% confidence intervals (CIs) and two-sided $P$-values were reported. An alpha value of $P<0.05$ was considered.

**Figure 1** Flowchart displaying the patient selection.

**Abbreviation:** ESCC, esophageal squamous cell carcinoma.
statistically significant. All statistical analyses were performed using the Statistical Package for the Social Sciences, version 19.0 (IBM Corporation, Armonk, NY, USA).

Results

Overall study population

Baseline clinicopathological characteristics are listed in Table 1. A total of 459 patients (341 male and 118 female) with locoregional ESCC were enrolled. The median age of the cohort at initial diagnosis was 59 years. Tumors were pathologically confirmed as being of highly or moderately differentiated grade in 351 patients (76.5%). By anatomic site, 287 tumors (62.5%) were limited to the middle third of the esophagus. Forty-one (8.9%), 217 (47.3%), and 201 (43.8%) patients were categorized as having American Joint Committee on Cancer/Union for International Cancer Control stage I, stage II, and stage III disease, respectively. Glasgow Prognostic Score (GPS) was also calculated, and most patients (n=357, 77.8%) presented with a presurgical GPS of zero. Overall, 289 patients (63%) were smokers and 158 were alcohol drinkers (34.3%). Among all the participants, 60 patients (13.1%) were evaluated as underweight by BMI, 318 (69.3%) had normal weight, and 81 (17.6%) were overweight or obese.

In all, 378 patients (82.4%) underwent radical resection and the other 81 patients (17.6%) underwent surgery with postoperative treatment. Postoperative chemotherapy alone, radiotherapy alone, and concurrent chemoradiotherapy were used in 66 (14.3%), three (0.7%), and 12 (2.6%) patients, respectively. Cisplatin, nedaplatin, fluorouracil, paclitaxel, and docetaxel were the most commonly delivered chemotherapy agents.

Correlation of smoking with other clinicopathological features

A significant male predominance and female predominance were observed in ever smokers and never smokers, respectively. Advanced tumors (P=0.010), alcohol drinkers (P<0.001), and overweight or obese patients (P=0.022) were significantly higher among ever smokers (n=289) than never smokers. Among never smokers (n=170), 13 patients (7.6%) were evaluated as underweight by BMI, 122 (71.8%) had normal weight, and 35 (20.6%) were overweight or obese. Among ever smokers (n=289; median, 37 pack-years), 47 patients (16.3%) were evaluated as underweight by BMI, 196 (67.8%) had normal weight, and 46 (15.9%) were overweight or obese. The mean BMI values of never smokers and ever smokers were 22.67 and 21.74 kg/m², respectively (Student’s t-test, P=0.003).

Survival analyses

The median follow-up time was 44 months (range, 1.3–106.3 months). At the final follow-up time point, 255 patients had died. The median OS time for the entire patient group was 53.8 months, with 3- and 5-year OS rates of 58.2% and 47.3%, respectively. For the entire cohort, the median OS time for patients with low BMI (<18.5 kg/m²) and high BMI (≥18.5 kg/m²) was 29.8 and 60.9 months, respectively,
with the 5-year OS rates being 27.2% and 50%, respectively ($P=0.002$). Besides BMI, TNM stage, drinking, smoking, GPS, and treatment approach were indicated as prognostic factors in the univariate analysis of OS. Multivariate analysis of OS was then conducted to confirm the prognostic effect of BMI. After adjusting for these covariates, BMI as well as TNM stage remained as independent prognostic factors of OS (Table 2; Figure 2A). We found that patients with a low BMI ($<18.5 \text{ kg/m}^2$) had a 1.497 times greater mortality risk than those with a high BMI ($\geq 18.5 \text{ kg/m}^2$) (95% CI = 1.071–2.092, $P=0.018$).

In subgroup analysis of OS, the alpha value was defined as 0.025 (0.05/2) by Bonferroni adjustment. Among never smokers, univariate analysis revealed that underweight patients had a significantly shorter OS than non-underweight patients (5-year OS rates: 15.4% vs 57.3%, $P=0.009$) (Figure 2B). We further performed multivariate analysis of OS to explore the prognostic effect of BMI in never smokers. In addition to smoking status, TNM stage, alcohol consumption, GPS, and treatment approach that showed significance in the univariate analysis of the overall cohort were also included in the multivariate model. BMI was reconfirmed as an independent prognostic factor for never smokers with ESCC. Among never smokers, underweight patients (BMI $<18.5 \text{ kg/m}^2$) had a 2.218 times greater risk of mortality than the non-underweight (BMI $\geq 18.5 \text{ kg/m}^2$) patients (95% CI = 1.164–4.224, $P=0.015$) (Table 3).

Among ever smokers, non-underweight patients had a better OS than underweight patients, with only marginal statistical significance (5-year OS rates: 44.6% vs 40.8%,

<table>
<thead>
<tr>
<th>Variable</th>
<th>Univariate</th>
<th>Multivariate</th>
<th>Multivariate</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>$P$-value</td>
<td>HR 95% CI</td>
<td>$P$-value</td>
</tr>
<tr>
<td>Sex</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>Reference</td>
<td></td>
<td>Reference</td>
</tr>
<tr>
<td>Female</td>
<td>0.061</td>
<td>0.757</td>
<td>0.566</td>
</tr>
<tr>
<td>Age (years)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>$&lt;60$</td>
<td>Reference</td>
<td></td>
<td>Reference</td>
</tr>
<tr>
<td>$\geq 60$</td>
<td>0.193</td>
<td>1.177</td>
<td>0.921</td>
</tr>
<tr>
<td>Tumor grade</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I–II</td>
<td>Reference</td>
<td></td>
<td>Reference</td>
</tr>
<tr>
<td>III</td>
<td>0.144</td>
<td>1.232</td>
<td>0.931</td>
</tr>
<tr>
<td>TNM stage</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I</td>
<td>Reference</td>
<td></td>
<td>Reference</td>
</tr>
<tr>
<td>II</td>
<td>0.002*</td>
<td>3.394</td>
<td>1.579</td>
</tr>
<tr>
<td>III</td>
<td>$&lt;0.001*$</td>
<td>7.215</td>
<td>3.374</td>
</tr>
<tr>
<td>Tumor location</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Upper</td>
<td>Reference</td>
<td></td>
<td>Reference</td>
</tr>
<tr>
<td>Middle</td>
<td>0.818</td>
<td>0.949</td>
<td>0.608</td>
</tr>
<tr>
<td>Lower</td>
<td>0.569</td>
<td>0.869</td>
<td>0.536</td>
</tr>
<tr>
<td>Alcohol drinking</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>Reference</td>
<td></td>
<td>Reference</td>
</tr>
<tr>
<td>Yes</td>
<td>0.004*</td>
<td>1.452</td>
<td>1.128</td>
</tr>
<tr>
<td>Smoking status</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Never</td>
<td>Reference</td>
<td></td>
<td>Reference</td>
</tr>
<tr>
<td>Ever</td>
<td>0.028*</td>
<td>1.341</td>
<td>1.031</td>
</tr>
<tr>
<td>Body mass index (kg/m$^2$)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>$\geq 18.5$</td>
<td>Reference</td>
<td></td>
<td>Reference</td>
</tr>
<tr>
<td>$&lt;18.5$</td>
<td>0.002*</td>
<td>1.673</td>
<td>1.205</td>
</tr>
<tr>
<td>GPS</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>Reference</td>
<td></td>
<td>Reference</td>
</tr>
<tr>
<td>1–2</td>
<td>0.008*</td>
<td>1.459</td>
<td>1.102</td>
</tr>
<tr>
<td>Treatment</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Surgery alone</td>
<td>Reference</td>
<td></td>
<td>Reference</td>
</tr>
<tr>
<td>Surgery + adjuvant RT/CT</td>
<td>0.003*</td>
<td>1.573</td>
<td>1.166</td>
</tr>
</tbody>
</table>

Note: *$P<0.05$.

Abbreviations: CI, confidence interval; CT, chemotherapy; ESCC, esophageal squamous cell carcinoma; GPS, Glasgow Prognostic Score; HR, hazard ratio; OS, overall survival; RT, radiotherapy; TNM, Tumor-Node-Metastases.
$P = 0.074$) (Table 3; Figure 2C). However, we identified a significant survival difference between smokers with $\text{BMI} < 18$ kg/m$^2$ and $\geq 18$ kg/m$^2$: smokers with a low BMI had a significantly shorter OS than those with $\text{BMI} \geq 18$ kg/m$^2$ (5-year OS rates: 22.5% vs 45.2%, $P = 0.009$) (Figures 2D and 3). Multivariate analysis of OS demonstrated that $\text{BMI} < 18$ kg/m$^2$ was an independently unfavorable prognostic factor among ever smokers, after adjusting for

**Table 3** Univariate and multivariate analyses of OS stratified by smoking status

<table>
<thead>
<tr>
<th>Variable</th>
<th>Univariate</th>
<th>Multivariate</th>
<th>Alpha value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>OS time (months)</td>
<td>5-year OS rate (%)</td>
<td>$P$-value</td>
</tr>
<tr>
<td>Never smokers</td>
<td>$\text{BMI} \geq 18.5$ kg/m$^2$</td>
<td>100.7</td>
<td>57.3</td>
</tr>
<tr>
<td></td>
<td>$\text{BMI} &lt; 18.5$ kg/m$^2$</td>
<td>37.6</td>
<td>15.4</td>
</tr>
<tr>
<td>Ever smokers</td>
<td>$\text{BMI} \geq 18.5$ kg/m$^2$</td>
<td>50.2</td>
<td>44.6</td>
</tr>
<tr>
<td></td>
<td>$\text{BMI} &lt; 18.5$ kg/m$^2$</td>
<td>29.8</td>
<td>30.8</td>
</tr>
<tr>
<td></td>
<td>$\text{BMI} \geq 18$ kg/m$^2$</td>
<td>50.9</td>
<td>45.2</td>
</tr>
<tr>
<td></td>
<td>$\text{BMI} &lt; 18$ kg/m$^2$</td>
<td>27.4</td>
<td>22.5</td>
</tr>
</tbody>
</table>

*Note:* $P < 0.025$.

**Abbreviations:** BMI, body mass index; CI, confidence interval; HR, hazard ratio; OS, overall survival.
TNM stage, alcohol consumption, GPS, and treatment approach. Compared to those with BMI $\geq 18$ kg/m$^2$, low BMI (<18 kg/m$^2$) increased the mortality risk for ever smokers with ESCC to 1.656 (95% CI =1.085–2.526, $P=0.019$) (Table 3).

**Discussion**

BMI is a parameter that roughly reflects an individual’s nutritional status and can be feasibly and conveniently obtained in clinical practice. Recently, the role of BMI has been increasingly appreciated, as the strong relationship between BMI and the risk of ESCC was established in previous studies.\(^7\)\(^-\)\(^9\) In 2001, Gallus et al performed a large case–control study and reported that leanness appeared to be an indicator of ESCC.\(^9\) In 2008, Smith et al\(^7\) conducted a meta-analysis including ten studies and found significant inverse associations between BMI and the risk of ESCC in both Western and Asian populations. This finding was confirmed by Lahmann et al,\(^8\) who further showed that these associations were independent of smoking status.

Other than being an epidemiological risk factor, BMI was also recognized as a prognostic factor for ESCC. In the meta-analysis by Smith et al,\(^7\) the risk of mortality in ESCC decreased by 31% for a 5 kg/m$^2$ increase in BMI. French oncologists found that a low BMI (<18 kg/m$^2$) was associated with inferior survival in 87 ESCC cases with definitive chemoradiotherapy,\(^30\) which was consistent with data from another French study reported by Clavier et al.\(^31\) The poor prognosis of low BMI was also identified in two other Chinese studies.\(^28,29\) Consistent with these results, we also confirmed, in our large retrospective study, the unfavorable impact of low BMI (<18.5 kg/m$^2$) on survival in locoregional ESCC.

Although studies\(^28,29\) exploring the prognostic effect of BMI in ESCC showed encouraging results, the role of smoking status could not be ignored in the interpretation of BMI data for several critical reasons. First, smoking status might negatively affect individual body weight and BMI. Second, smoking status itself is a well-known risk factor and a potential prognostic factor as propounded by multiple studies.\(^14,22,32,33\) The complex interaction between BMI and smoking status of cancer patients has been revealed by several studies,\(^18–20\) although with inconsistent data. In addition, few studies have explored the influence of smoking status on the association between BMI and the risk of ESCC, with discordant results.\(^8,9,34\) However, to our best knowledge, the prognostic value of BMI stratified by smoking status in ESCC has thus far not been evaluated. Only one study has discussed this issue, but with respect to esophageal adenocarcinoma. In 2011, Yoon et al\(^26\) retrospectively analyzed cases of esophageal adenocarcinoma from the Mayo Esophageal Cancer Outcomes Database. In that study, obesity (BMI $\geq 30$ kg/m$^2$) was independently associated with a worsened prognosis among never smokers, but not among ever smokers. Accordingly, in our study, the adverse impact of BMI <18.5 kg/m$^2$ was limited to never smokers in the
stratified analysis. Multivariate survival analysis using the Cox model showed that low BMI (<18.5 kg/m²) was independently associated with impaired OS. By contrast, low BMI (<18.5 kg/m²) was not a significantly poor prognostic factor of OS (P=0.074) among ever smokers. Therefore, our results explored and highlighted the importance of smoking status in the interpretation of BMI data in patients with ESCC. Furthermore, the hazard ratio of low BMI (<18.5 kg/m²) increased from 1.497 for the entire cohort to 2.218 for never smokers, indicating that the prognostic effect was amplified with the exclusion of ever smokers.

A possible explanation for this interesting finding was proposed by the authors from Mayo Clinic.³⁵ Leptin could promote tumor progression and invasion in digestive cancers, whereas cigarette smoking could decrease the circulating leptin and enhance its receptors. Thus, Yoon et al³⁶ considered the prognostic impact of obesity was weakened in esophageal adenocarcinoma by smoking. However, this explanation could not be merely extended to ESCC owing to its apparent etiological and epidemiological differences. Because of a relatively high prevalence of cancer-related dysphagia and cachexia, patients with ESCC might present with low BMI in contrast to those with esophageal adenocarcinoma. On the other hand, the BMI of the Asian population is considered lower than that of the Western population.²⁶,²⁸ These aspects must be taken into consideration while determining the relationship between BMI, smoking, and prognosis in ESCC.

Several population-based studies have explored the interaction between smoking and BMI, as smoking has shown to be associated with decreased BMI. Wehby et al³³ applied genetic tools to identify the effects of smoking on body weight and detected heterogeneity in these effects across the BMI distribution in a Norwegian population. Their results revealed that smoking had a negative impact on BMI of the population with high BMI.³⁵ Kasteridis and Yen³⁶ analyzed the population from the Behavioral Risk Factor Surveillance Survey and showed a positive association between body weight gain and smoking cessation. Wang³⁶ explored the data obtained from the China Health and Nutrition Survey 1991–2011 and found a positive effect of smoking on overweight and healthy weight. Su et al³⁷ found that smoking had an effect on decreasing BMI of middle-aged and older Chinese males, based on the data from the Chinese Physical and Psychological Database. In addition, the weight-reducing effect of smoking on BMI has been further explored in single-nucleotide polymorphism studies.³⁸ Smoking status was found to modify the association between 15q25 variant of CHRNA5-CHRNA3-CHRNB4 gene and BMI, providing reliable evidence that smoking exposure reduces the BMI.³⁹

Based on the available BMI-smoking data, we suggested that the reduction of BMI due to smoking weakened its impact of survival in ever smokers with ESCC. The present study provided evidence to support this opinion. Our data showed a relatively lower BMI for ever smokers than never smokers (mean BMI: 22.67 vs 21.74 kg/m²; Student’s t-test, P=0.003). We then hypothesized that the significant prognostic effect of low BMI could be detected if we decreased the BMI cutoff value. In order to validate our hypothesis, we regrouped the participants into two groups, patients with BMI ≥18 kg/m² and those with BMI <18 kg/m², by referring to the experience of a previous study.³⁰ Low BMI (<18 kg/m²) was found to be independently associated with poor prognosis among ever smokers, even after adjusting for other covariates. This finding partly suggested that the prognostic effect of BMI in ESCC was modified but not abolished in ever smokers with ESCC. The results in Yoon’s study might be different if they had changed the definition of obese by altering the categorization of BMI.²⁶ Therefore, adequate classification of BMI is important in certain populations such as in Asians, in ESCC, or in ever smokers, in order to gain accurate prognostic information of BMI.

The main merits of our study include the relatively large sample size and histological homogeneity with regard to ESCC, representing a clinical entity in the Chinese patient population. The demographic characteristics of our cohort were in line with previous data.²⁴ BMI was calculated from body weight and height prospectively measured by trained nurses at a uniform time point relative to surgery, instead of relying on self-reported weight and height measurements as in another study.³⁵ In addition, patients who underwent neoadjuvant therapy were excluded to avoid the situation of potential treatment-related BMI decrease.

Our study also has some limitations. First, there was inherent bias owing to the study’s retrospective design, although the height and weight measurements were prospectively recorded. Second, the significant male predominance in our cohort might limit the applicability of our findings to females, especially among ever smokers. Third, we did not further discuss the association between BMI and postoperative comorbidities due to insufficient data. Finally, the low percentage (13.1% overall, 7.1% in never smokers) of underweight patients (BMI <18.5 kg/m²) should be acknowledged. Therefore, it is important to validate our findings in a prospective study from an independent cohort.
Conclusion
We conclude that there is a substantial prognostic effect of BMI on Chinese patients with ESCC, after accounting for the effects of other factors. The adverse effect of low BMI on survival in ESCC was robust and amplified in never smokers, and this effect remained significant in ever smokers. We also found that smokers showed a relatively low BMI, which probably contributed to the modifications of smoking on the prognostic effect of BMI in ESCC. Genetic tools should be applied to elucidate the biologic mechanisms underlying the interaction between smoking, BMI, and cancer prognosis. In particular, the prognostic information of BMI was important to facilitate risk stratification, refine postoperative treatment approach, and assist with nutritional support for patients with ESCC.

Disclosure
The authors report no conflicts of interest in this work.

References


